Compile Data Set for Download or QSAR
Found 135 of affinity data for UniProtKB/TrEMBL: P0DTC1
TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM553970(US11325916, Example 1)
Show SMILES CC(C)C[C@H](N(C)C(=O)[C@H](Cc1ccc(F)cc1)NC(=O)OCc1ccccc1)C(=O)N1C[C@]2(C[C@H]1C#N)C(=O)Nc1ccccc21
Show InChI InChI=1S/C36H38FN5O5/c1-23(2)17-31(33(44)42-22-36(19-27(42)20-38)28-11-7-8-12-29(28)39-34(36)45)41(3)32(43)30(18-24-13-15-26(37)16-14-24)40-35(46)47-21-25-9-5-4-6-10-25/h4-16,23,27,30-31H,17-19,21-22H2,1-3H3,(H,39,45)(H,40,46)/t27-,30-,31-,36-/m0/s1
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM553971(US11325916, Example 2)
Show SMILES CC(C)C[C@H](N(C)C(=O)[C@H](Cc1ccc(F)cc1)NC(=O)OCc1ccccc1)C(=O)N1C[C@]2(C[C@H]1NC=O)C(=O)Nc1ccccc21
Show InChI InChI=1S/C36H40FN5O6/c1-23(2)17-30(33(45)42-21-36(19-31(42)38-22-43)27-11-7-8-12-28(27)39-34(36)46)41(3)32(44)29(18-24-13-15-26(37)16-14-24)40-35(47)48-20-25-9-5-4-6-10-25/h4-16,22-23,29-31H,17-21H2,1-3H3,(H,38,43)(H,39,46)(H,40,47)/t29-,30-,31-,36-/m0/s1
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM553972(US11325916, Example 3)
Show SMILES COC(=O)N[C@@H](Cc1ccc(F)cc1)C(=O)N(C)[C@@H](CC(C)C)C(=O)N1C[C@]2(C[C@H]1C#N)C(=O)Nc1ccccc21
Show InChI InChI=1S/C30H34FN5O5/c1-18(2)13-25(35(3)26(37)24(34-29(40)41-4)14-19-9-11-20(31)12-10-19)27(38)36-17-30(15-21(36)16-32)22-7-5-6-8-23(22)33-28(30)39/h5-12,18,21,24-25H,13-15,17H2,1-4H3,(H,33,39)(H,34,40)/t21-,24-,25-,30-/m0/s1
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM553973(US11325916, Example 4)
Show SMILES CC(C)C[C@H](N(C)C(=O)[C@H](Cc1ccc(F)cc1)NC(=O)c1cc(C)on1)C(=O)N1C[C@]2(C[C@H]1NC=O)C(=O)Nc1ccccc21
Show InChI InChI=1S/C33H37FN6O6/c1-19(2)13-27(31(44)40-17-33(16-28(40)35-18-41)23-7-5-6-8-24(23)37-32(33)45)39(4)30(43)26(15-21-9-11-22(34)12-10-21)36-29(42)25-14-20(3)46-38-25/h5-12,14,18-19,26-28H,13,15-17H2,1-4H3,(H,35,41)(H,36,42)(H,37,45)/t26-,27-,28-,33-/m0/s1
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM553974(US11325916, Example 5 | US11325916, Example 6)
Show SMILES CN([C@@H](CC(C)(C)C)C(=O)N1C[C@]2(C[C@H]1C#N)C(=O)Nc1ccccc21)C(=O)[C@H](Cc1ccc(F)cc1)NC(=O)OCc1ccccc1
Show InChI InChI=1S/C37H40FN5O5/c1-36(2,3)20-31(33(45)43-23-37(19-27(43)21-39)28-12-8-9-13-29(28)40-34(37)46)42(4)32(44)30(18-24-14-16-26(38)17-15-24)41-35(47)48-22-25-10-6-5-7-11-25/h5-17,27,30-31H,18-20,22-23H2,1-4H3,(H,40,46)(H,41,47)/t27-,30-,31-,37-/m0/s1
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM553974(US11325916, Example 5 | US11325916, Example 6)
Show SMILES CN([C@@H](CC(C)(C)C)C(=O)N1C[C@]2(C[C@H]1C#N)C(=O)Nc1ccccc21)C(=O)[C@H](Cc1ccc(F)cc1)NC(=O)OCc1ccccc1
Show InChI InChI=1S/C37H40FN5O5/c1-36(2,3)20-31(33(45)43-23-37(19-27(43)21-39)28-12-8-9-13-29(28)40-34(37)46)42(4)32(44)30(18-24-14-16-26(38)17-15-24)41-35(47)48-22-25-10-6-5-7-11-25/h5-17,27,30-31H,18-20,22-23H2,1-4H3,(H,40,46)(H,41,47)/t27-,30-,31-,37-/m0/s1
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM553976(US11325916, Example 7)
Show SMILES CN([C@@H](CC(C)(C)C)C(=O)N1C[C@]2(C[C@H]1C#N)C(=O)Nc1ccccc21)C(=O)[C@H](Cc1ccc(F)cc1)NC(=O)c1cc2c(F)cc(F)c(F)c2[nH]1
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM553977(US11325916, Example 8)
Show SMILES CN([C@@H](CC(C)(C)C)C(=O)N1C[C@]2(C[C@H]1C#N)C(=O)Nc1ccccc21)C(=O)[C@H](Cc1ccc(F)cc1)NC(=O)NC1CC1
Show InChI InChI=1S/C33H39FN6O4/c1-32(2,3)17-27(29(42)40-19-33(16-23(40)18-35)24-7-5-6-8-25(24)37-30(33)43)39(4)28(41)26(38-31(44)36-22-13-14-22)15-20-9-11-21(34)12-10-20/h5-12,22-23,26-27H,13-17,19H2,1-4H3,(H,37,43)(H2,36,38,44)/t23-,26-,27-,33-/m0/s1
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM553978(US11325916, Example 9)
Show SMILES CN([C@@H](CC(C)(C)C)C(=O)N1C[C@]2(C[C@H]1C#N)C(=O)Nc1ccccc21)C(=O)[C@H](Cc1ccc(F)cc1)n1cc(nn1)C1CC1
Show InChI InChI=1S/C34H38FN7O3/c1-33(2,3)17-29(31(44)41-20-34(16-24(41)18-36)25-7-5-6-8-26(25)37-32(34)45)40(4)30(43)28(15-21-9-13-23(35)14-10-21)42-19-27(38-39-42)22-11-12-22/h5-10,13-14,19,22,24,28-29H,11-12,15-17,20H2,1-4H3,(H,37,45)/t24-,28-,29-,34-/m0/s1
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM553980(US11325916, Example 11)
Show SMILES CC(C)C[C@H](N(C)C(=O)[C@@H](NC(=O)OCc1ccccc1)C(C)(C)C)C(=O)N1C[C@]2(C[C@H]1C#N)C(=O)Nc1ccccc21
Show InChI InChI=1S/C33H41N5O5/c1-21(2)16-26(28(39)38-20-33(17-23(38)18-34)24-14-10-11-15-25(24)35-30(33)41)37(6)29(40)27(32(3,4)5)36-31(42)43-19-22-12-8-7-9-13-22/h7-15,21,23,26-27H,16-17,19-20H2,1-6H3,(H,35,41)(H,36,42)/t23-,26-,27+,33-/m0/s1
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM553981(US11325916, Example 12)
Show SMILES CC(C)C[C@H](N(C)C(=O)[C@@H](NC(=O)C(F)(F)F)C(C)(C)C)C(=O)N1C[C@]2(C[C@H]1C#N)C(=O)Nc1ccccc21
Show InChI InChI=1S/C27H34F3N5O4/c1-15(2)11-19(34(6)22(37)20(25(3,4)5)33-24(39)27(28,29)30)21(36)35-14-26(12-16(35)13-31)17-9-7-8-10-18(17)32-23(26)38/h7-10,15-16,19-20H,11-12,14H2,1-6H3,(H,32,38)(H,33,39)/t16-,19-,20+,26-/m0/s1
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM553982(US11325916, Example 13)
Show SMILES COC(=O)N[C@H](C(=O)N(C)[C@@H](CC(C)C)C(=O)N1C[C@]2(C[C@H]1C#N)C(=O)Nc1ccccc21)C(C)(C)C
Show InChI InChI=1S/C27H37N5O5/c1-16(2)12-20(31(6)23(34)21(26(3,4)5)30-25(36)37-7)22(33)32-15-27(13-17(32)14-28)18-10-8-9-11-19(18)29-24(27)35/h8-11,16-17,20-21H,12-13,15H2,1-7H3,(H,29,35)(H,30,36)/t17-,20-,21+,27-/m0/s1
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM553983(US11325916, Example 14)
Show SMILES CC(C)C[C@H](N(C)C(=O)[C@H](CC1CC1)NC(=O)OCc1ccccc1)C(=O)N1C[C@]2(C[C@H]1C#N)C(=O)Nc1ccccc21
Show InChI InChI=1S/C33H39N5O5/c1-21(2)15-28(30(40)38-20-33(17-24(38)18-34)25-11-7-8-12-26(25)35-31(33)41)37(3)29(39)27(16-22-13-14-22)36-32(42)43-19-23-9-5-4-6-10-23/h4-12,21-22,24,27-28H,13-17,19-20H2,1-3H3,(H,35,41)(H,36,42)/t24-,27-,28-,33-/m0/s1
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM553984(US11325916, Example 15)
Show SMILES CC(C)C[C@H](N(C)C(=O)[C@H](CC1CC1)NC(=O)C(F)(F)F)C(=O)N1C[C@]2(C[C@H]1C#N)C(=O)Nc1ccccc21
Show InChI InChI=1S/C27H32F3N5O4/c1-15(2)10-21(34(3)22(36)20(11-16-8-9-16)33-25(39)27(28,29)30)23(37)35-14-26(12-17(35)13-31)18-6-4-5-7-19(18)32-24(26)38/h4-7,15-17,20-21H,8-12,14H2,1-3H3,(H,32,38)(H,33,39)/t17-,20-,21-,26-/m0/s1
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM553985(US11325916, Example 16)
Show SMILES COC(=O)N[C@@H](CC1CC1)C(=O)N(C)[C@@H](CC(C)C)C(=O)N1C[C@]2(C[C@H]1C#N)C(=O)Nc1ccccc21
Show InChI InChI=1S/C27H35N5O5/c1-16(2)11-22(31(3)23(33)21(12-17-9-10-17)30-26(36)37-4)24(34)32-15-27(13-18(32)14-28)19-7-5-6-8-20(19)29-25(27)35/h5-8,16-18,21-22H,9-13,15H2,1-4H3,(H,29,35)(H,30,36)/t18-,21-,22-,27-/m0/s1
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM553986(US11325916, Example 17)
Show SMILES CC(C)C[C@H](N(C)C(=O)[C@H](CC1CC1)NC(=O)c1ccc(F)cc1)C(=O)N1C[C@]2(C[C@H]1C#N)C(=O)Nc1ccccc21
Show InChI InChI=1S/C32H36FN5O4/c1-19(2)14-27(30(41)38-18-32(16-23(38)17-34)24-6-4-5-7-25(24)36-31(32)42)37(3)29(40)26(15-20-8-9-20)35-28(39)21-10-12-22(33)13-11-21/h4-7,10-13,19-20,23,26-27H,8-9,14-16,18H2,1-3H3,(H,35,39)(H,36,42)/t23-,26-,27-,32-/m0/s1
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM553987(US11325916, Example 18)
Show SMILES CC(C)C[C@H](N(C)C(=O)[C@H](Cc1ccc(F)cc1)NC(=O)c1cnccn1)C(=O)N1C[C@]2(C[C@H]1C#N)C(=O)Nc1ccccc21
Show InChI InChI=1S/C33H34FN7O4/c1-20(2)14-28(31(44)41-19-33(16-23(41)17-35)24-6-4-5-7-25(24)39-32(33)45)40(3)30(43)26(15-21-8-10-22(34)11-9-21)38-29(42)27-18-36-12-13-37-27/h4-13,18,20,23,26,28H,14-16,19H2,1-3H3,(H,38,42)(H,39,45)/t23-,26-,28-,33-/m0/s1
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM553988(US11325916, Example 19)
Show SMILES CC(C)C[C@H](N(C)C(=O)[C@H](Cc1ccc(F)cc1)NC(=O)c1ccn(C)n1)C(=O)N1C[C@]2(C[C@H]1C#N)C(=O)Nc1ccccc21
Show InChI InChI=1S/C33H36FN7O4/c1-20(2)15-28(31(44)41-19-33(17-23(41)18-35)24-7-5-6-8-25(24)37-32(33)45)40(4)30(43)27(16-21-9-11-22(34)12-10-21)36-29(42)26-13-14-39(3)38-26/h5-14,20,23,27-28H,15-17,19H2,1-4H3,(H,36,42)(H,37,45)/t23-,27-,28-,33-/m0/s1
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM553990(US11325916, Example 20)
Show SMILES CC(C)C[C@H](N(C)C(=O)[C@@H](NC(=O)OCc1ccccc1)C1CCCCC1)C(=O)N1C[C@]2(C[C@H]1C#N)C(=O)Nc1ccccc21
Show InChI InChI=1S/C35H43N5O5/c1-23(2)18-29(31(41)40-22-35(19-26(40)20-36)27-16-10-11-17-28(27)37-33(35)43)39(3)32(42)30(25-14-8-5-9-15-25)38-34(44)45-21-24-12-6-4-7-13-24/h4,6-7,10-13,16-17,23,25-26,29-30H,5,8-9,14-15,18-19,21-22H2,1-3H3,(H,37,43)(H,38,44)/t26-,29-,30-,35-/m0/s1
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM553992(US11325916, Example 21)
Show SMILES CC(C)C[C@H](N(C)C(=O)[C@@H](NC(=O)C(F)(F)F)C1CCCCC1)C(=O)N1C[C@]2(C[C@H]1C#N)C(=O)Nc1ccccc21
Show InChI InChI=1S/C29H36F3N5O4/c1-17(2)13-22(36(3)25(39)23(18-9-5-4-6-10-18)35-27(41)29(30,31)32)24(38)37-16-28(14-19(37)15-33)20-11-7-8-12-21(20)34-26(28)40/h7-8,11-12,17-19,22-23H,4-6,9-10,13-14,16H2,1-3H3,(H,34,40)(H,35,41)/t19-,22-,23-,28-/m0/s1
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM553993(US11325916, Example 22)
Show SMILES CC(C)C[C@H](N(C)C(=O)C(NC(=O)OCc1ccccc1)c1ccccc1)C(=O)N1C[C@]2(C[C@H]1C#N)C(=O)Nc1ccccc21
Show InChI InChI=1S/C35H37N5O5/c1-23(2)18-29(31(41)40-22-35(19-26(40)20-36)27-16-10-11-17-28(27)37-33(35)43)39(3)32(42)30(25-14-8-5-9-15-25)38-34(44)45-21-24-12-6-4-7-13-24/h4-17,23,26,29-30H,18-19,21-22H2,1-3H3,(H,37,43)(H,38,44)/t26-,29-,30?,35-/m0/s1
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM553994(US11325916, Example 23)
Show SMILES COC(=O)N[C@@H](C1CCCCC1)C(=O)N(C)[C@@H](CC(C)C)C(=O)N1C[C@]2(C[C@H]1C#N)C(=O)Nc1ccccc21
Show InChI InChI=1S/C29H39N5O5/c1-18(2)14-23(33(3)26(36)24(32-28(38)39-4)19-10-6-5-7-11-19)25(35)34-17-29(15-20(34)16-30)21-12-8-9-13-22(21)31-27(29)37/h8-9,12-13,18-20,23-24H,5-7,10-11,14-15,17H2,1-4H3,(H,31,37)(H,32,38)/t20-,23-,24-,29-/m0/s1
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM553995(US11325916, Example 24)
Show SMILES CC(C)C[C@H](N(C)C(=O)[C@H](CC1CCC1)NC(=O)OCc1ccccc1)C(=O)N1C[C@]2(C[C@H]1C#N)C(=O)Nc1ccccc21
Show InChI InChI=1S/C34H41N5O5/c1-22(2)16-29(31(41)39-21-34(18-25(39)19-35)26-14-7-8-15-27(26)36-32(34)42)38(3)30(40)28(17-23-12-9-13-23)37-33(43)44-20-24-10-5-4-6-11-24/h4-8,10-11,14-15,22-23,25,28-29H,9,12-13,16-18,20-21H2,1-3H3,(H,36,42)(H,37,43)/t25-,28-,29-,34-/m0/s1
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM553996(US11325916, Example 25)
Show SMILES CC(C)C[C@H](N(C)C(=O)[C@H](CC(C)(C)C)NC(=O)OCc1ccccc1)C(=O)N1C[C@]2(C[C@H]1C#N)C(=O)Nc1ccccc21
Show InChI InChI=1S/C34H43N5O5/c1-22(2)16-28(30(41)39-21-34(17-24(39)19-35)25-14-10-11-15-26(25)36-31(34)42)38(6)29(40)27(18-33(3,4)5)37-32(43)44-20-23-12-8-7-9-13-23/h7-15,22,24,27-28H,16-18,20-21H2,1-6H3,(H,36,42)(H,37,43)/t24-,27-,28-,34-/m0/s1
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM553997(US11325916, Example 26)
Show SMILES CC(C)C[C@H](N(C)C(=O)[C@H](CC(C)(C)C)NC(=O)C(F)(F)F)C(=O)N1C[C@]2(C[C@H]1C#N)C(=O)Nc1ccccc21
Show InChI InChI=1S/C28H36F3N5O4/c1-16(2)11-21(35(6)22(37)20(13-26(3,4)5)34-25(40)28(29,30)31)23(38)36-15-27(12-17(36)14-32)18-9-7-8-10-19(18)33-24(27)39/h7-10,16-17,20-21H,11-13,15H2,1-6H3,(H,33,39)(H,34,40)/t17-,20-,21-,27-/m0/s1
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM553998(US11325916, Example 27)
Show SMILES CC(C)C[C@H](N(C)C(=O)[C@H](CC1CCC1)NC(=O)C(F)(F)F)C(=O)N1C[C@]2(C[C@H]1C#N)C(=O)Nc1ccccc21
Show InChI InChI=1S/C28H34F3N5O4/c1-16(2)11-22(35(3)23(37)21(12-17-7-6-8-17)34-26(40)28(29,30)31)24(38)36-15-27(13-18(36)14-32)19-9-4-5-10-20(19)33-25(27)39/h4-5,9-10,16-18,21-22H,6-8,11-13,15H2,1-3H3,(H,33,39)(H,34,40)/t18-,21-,22-,27-/m0/s1
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM553999(US11325916, Example 28)
Show SMILES CN([C@@H](Cc1ccccc1)C(=O)N1C[C@]2(C[C@H]1C#N)C(=O)Nc1ccccc21)C(=O)[C@@H](NC(=O)OCc1ccccc1)C(C)(C)C
Show InChI InChI=1S/C36H39N5O5/c1-35(2,3)30(39-34(45)46-22-25-15-9-6-10-16-25)32(43)40(4)29(19-24-13-7-5-8-14-24)31(42)41-23-36(20-26(41)21-37)27-17-11-12-18-28(27)38-33(36)44/h5-18,26,29-30H,19-20,22-23H2,1-4H3,(H,38,44)(H,39,45)/t26-,29-,30+,36-/m0/s1
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM554000(US11325916, Example 29)
Show SMILES CN([C@@H](Cc1ccccc1)C(=O)N1C[C@]2(C[C@H]1C#N)C(=O)Nc1ccccc21)C(=O)[C@@H](N)C(C)(C)C
Show InChI InChI=1S/C28H33N5O3/c1-27(2,3)23(30)25(35)32(4)22(14-18-10-6-5-7-11-18)24(34)33-17-28(15-19(33)16-29)20-12-8-9-13-21(20)31-26(28)36/h5-13,19,22-23H,14-15,17,30H2,1-4H3,(H,31,36)/t19-,22-,23+,28-/m0/s1
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM554001(US11325916, Example 30)
Show SMILES CN([C@@H](Cc1ccccc1)C(=O)N1C[C@]2(C[C@H]1C#N)C(=O)Nc1ccccc21)C(=O)[C@@H](NCc1cc(F)c(F)cc1F)C(C)(C)C
Show InChI InChI=1S/C35H36F3N5O3/c1-34(2,3)30(40-19-22-15-26(37)27(38)16-25(22)36)32(45)42(4)29(14-21-10-6-5-7-11-21)31(44)43-20-35(17-23(43)18-39)24-12-8-9-13-28(24)41-33(35)46/h5-13,15-16,23,29-30,40H,14,17,19-20H2,1-4H3,(H,41,46)/t23-,29-,30+,35-/m0/s1
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM554002(US11325916, Example 31)
Show SMILES CC(C)OC(=O)N[C@H](C(=O)N(C)[C@@H](Cc1ccccc1)C(=O)N1C[C@]2(C[C@H]1C#N)C(=O)Nc1ccccc21)C(C)(C)C
Show InChI InChI=1S/C32H39N5O5/c1-20(2)42-30(41)35-26(31(3,4)5)28(39)36(6)25(16-21-12-8-7-9-13-21)27(38)37-19-32(17-22(37)18-33)23-14-10-11-15-24(23)34-29(32)40/h7-15,20,22,25-26H,16-17,19H2,1-6H3,(H,34,40)(H,35,41)/t22-,25-,26+,32-/m0/s1
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM554003(US11325916, Example 32)
Show SMILES CC(C)C[C@H](N(C)C(=O)[C@H](CC(C)(C)C)N(C)C(=O)OCc1ccccc1)C(=O)N1C[C@]2(C[C@H]1C#N)C(=O)Nc1ccccc21
Show InChI InChI=1S/C35H45N5O5/c1-23(2)17-28(31(42)40-22-35(18-25(40)20-36)26-15-11-12-16-27(26)37-32(35)43)38(6)30(41)29(19-34(3,4)5)39(7)33(44)45-21-24-13-9-8-10-14-24/h8-16,23,25,28-29H,17-19,21-22H2,1-7H3,(H,37,43)/t25-,28-,29-,35-/m0/s1
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM554005(US11325916, Example 33)
Show SMILES CC(C)C[C@H](N(C)C(=O)[C@H](CC(C)(C)C)N(C)C(=O)C(F)(F)F)C(=O)N1C[C@]2(C[C@H]1C#N)C(=O)Nc1ccccc21
Show InChI InChI=1S/C29H38F3N5O4/c1-17(2)12-21(35(6)23(38)22(14-27(3,4)5)36(7)26(41)29(30,31)32)24(39)37-16-28(13-18(37)15-33)19-10-8-9-11-20(19)34-25(28)40/h8-11,17-18,21-22H,12-14,16H2,1-7H3,(H,34,40)/t18-,21-,22-,28-/m0/s1
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM554006(US11325916, Example 34)
Show SMILES CC(C)C[C@H](N(C)C(=O)[C@H](CC(C)(C)C)NC(=O)c1ccc(F)cc1)C(=O)N1C[C@]2(C[C@H]1C#N)C(=O)Nc1ccccc21
Show InChI InChI=1S/C33H40FN5O4/c1-20(2)15-27(30(42)39-19-33(16-23(39)18-35)24-9-7-8-10-25(24)37-31(33)43)38(6)29(41)26(17-32(3,4)5)36-28(40)21-11-13-22(34)14-12-21/h7-14,20,23,26-27H,15-17,19H2,1-6H3,(H,36,40)(H,37,43)/t23-,26-,27-,33-/m0/s1
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM554007(US11325916, Example 35)
Show SMILES CC(C)C[C@H](N(C)C(=O)[C@H](CC1CCC1)NC(=O)c1ccc(F)cc1)C(=O)N1C[C@]2(C[C@H]1C#N)C(=O)Nc1ccccc21
Show InChI InChI=1S/C33H38FN5O4/c1-20(2)15-28(31(42)39-19-33(17-24(39)18-35)25-9-4-5-10-26(25)37-32(33)43)38(3)30(41)27(16-21-7-6-8-21)36-29(40)22-11-13-23(34)14-12-22/h4-5,9-14,20-21,24,27-28H,6-8,15-17,19H2,1-3H3,(H,36,40)(H,37,43)/t24-,27-,28-,33-/m0/s1
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM554008(US11325916, Example 36)
Show SMILES CC(C)C[C@H](NC(=O)[C@@H](NC(=O)OCc1ccccc1)C(C)(C)C)C(=O)N1C[C@]2(C[C@H]1C#N)C(=O)Nc1ccccc21
Show InChI InChI=1S/C32H39N5O5/c1-20(2)15-25(34-27(38)26(31(3,4)5)36-30(41)42-18-21-11-7-6-8-12-21)28(39)37-19-32(16-22(37)17-33)23-13-9-10-14-24(23)35-29(32)40/h6-14,20,22,25-26H,15-16,18-19H2,1-5H3,(H,34,38)(H,35,40)(H,36,41)/t22-,25-,26+,32-/m0/s1
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM554009(US11325916, Example 37)
Show SMILES CC(C)(C)C[C@H](NC(=O)[C@H](CC1CC1)NS(=O)(=O)C1CC1)C(=O)N1C[C@]2(C[C@H]1C#N)C(=O)Nc1ccccc21
Show InChI InChI=1S/C28H37N5O5S/c1-27(2,3)14-23(30-24(34)22(12-17-8-9-17)32-39(37,38)19-10-11-19)25(35)33-16-28(13-18(33)15-29)20-6-4-5-7-21(20)31-26(28)36/h4-7,17-19,22-23,32H,8-14,16H2,1-3H3,(H,30,34)(H,31,36)/t18-,22-,23-,28-/m0/s1
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM554011(US11325916, Example 38)
Show SMILES CC(C)(C)C[C@H](NC(=O)[C@H](CC1CC1)NC(=O)NC1CC1)C(=O)N1C[C@]2(C[C@H]1C#N)C(=O)Nc1ccccc21
Show InChI InChI=1S/C29H38N6O4/c1-28(2,3)14-23(32-24(36)22(12-17-8-9-17)34-27(39)31-18-10-11-18)25(37)35-16-29(13-19(35)15-30)20-6-4-5-7-21(20)33-26(29)38/h4-7,17-19,22-23H,8-14,16H2,1-3H3,(H,32,36)(H,33,38)(H2,31,34,39)/t19-,22-,23-,29-/m0/s1
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM554012(US11325916, Example 39)
Show SMILES CN([C@@H](CC(C)(C)C)C(=O)N1C[C@]2(C[C@H]1C#N)C(=O)Nc1ccccc21)C(=O)[C@H](Cc1ccc(F)cc1)NC(=O)c1cc(C)on1
Show InChI InChI=1S/C34H37FN6O5/c1-20-14-26(39-46-20)29(42)37-27(15-21-10-12-22(35)13-11-21)30(43)40(5)28(17-33(2,3)4)31(44)41-19-34(16-23(41)18-36)24-8-6-7-9-25(24)38-32(34)45/h6-14,23,27-28H,15-17,19H2,1-5H3,(H,37,42)(H,38,45)/t23-,27-,28-,34-/m0/s1
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM554013(US11325916, Example 40)
Show SMILES CC(C)C[C@H](N(C)C(=O)[C@@H](NC(=O)c1cc(C)on1)C1CCCCC1)C(=O)N1C[C@]2(C[C@H]1C#N)C(=O)Nc1ccccc21
Show InChI InChI=1S/C32H40N6O5/c1-19(2)14-26(29(40)38-18-32(16-22(38)17-33)23-12-8-9-13-24(23)34-31(32)42)37(4)30(41)27(21-10-6-5-7-11-21)35-28(39)25-15-20(3)43-36-25/h8-9,12-13,15,19,21-22,26-27H,5-7,10-11,14,16,18H2,1-4H3,(H,34,42)(H,35,39)/t22-,26-,27-,32-/m0/s1
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM554014(US11325916, Example 41)
Show SMILES CC(C)C[C@H](N(C)C(=O)[C@H](CC1CC1)NC(C)=O)C(=O)N1C[C@]2(C[C@H]1C#N)C(=O)Nc1ccccc21
Show InChI InChI=1S/C27H35N5O4/c1-16(2)11-23(31(4)24(34)22(29-17(3)33)12-18-9-10-18)25(35)32-15-27(13-19(32)14-28)20-7-5-6-8-21(20)30-26(27)36/h5-8,16,18-19,22-23H,9-13,15H2,1-4H3,(H,29,33)(H,30,36)/t19-,22-,23-,27-/m0/s1
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM554015(US11325916, Example 42)
Show SMILES CC(C)C[C@H](N(C)C(=O)[C@H](CC1CCC1)NC(=O)C(C)(C)C)C(=O)N1C[C@]2(C[C@H]1C#N)C(=O)Nc1ccccc21
Show InChI InChI=1S/C31H43N5O4/c1-19(2)14-25(35(6)26(37)24(15-20-10-9-11-20)34-28(39)30(3,4)5)27(38)36-18-31(16-21(36)17-32)22-12-7-8-13-23(22)33-29(31)40/h7-8,12-13,19-21,24-25H,9-11,14-16,18H2,1-6H3,(H,33,40)(H,34,39)/t21-,24-,25-,31-/m0/s1
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM554016(US11325916, Example 43)
Show SMILES CC(C)C[C@H](N(C)C(=O)[C@H](CC(C)(C)C)NC(=O)C(C)(C)C)C(=O)N1C[C@]2(C[C@H]1C#N)C(=O)Nc1ccccc21
Show InChI InChI=1S/C31H45N5O4/c1-19(2)14-24(35(9)25(37)23(16-29(3,4)5)34-27(39)30(6,7)8)26(38)36-18-31(15-20(36)17-32)21-12-10-11-13-22(21)33-28(31)40/h10-13,19-20,23-24H,14-16,18H2,1-9H3,(H,33,40)(H,34,39)/t20-,23-,24-,31-/m0/s1
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM554017(US11325916, Example 44)
Show SMILES CC(C)C[C@H](N(C)C(=O)[C@H](CC(C)(C)C)N(C)C(C)=O)C(=O)N1C[C@]2(C[C@H]1C#N)C(=O)Nc1ccccc21
Show InChI InChI=1S/C29H41N5O4/c1-18(2)13-23(33(8)25(36)24(15-28(4,5)6)32(7)19(3)35)26(37)34-17-29(14-20(34)16-30)21-11-9-10-12-22(21)31-27(29)38/h9-12,18,20,23-24H,13-15,17H2,1-8H3,(H,31,38)/t20-,23-,24-,29-/m0/s1
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM554018(US11325916, Example 45)
Show SMILES CC(C)C[C@H](N(C)C(=O)[C@H](CC1CCC1)NC(=O)c1cc2c(F)cc(F)c(F)c2[nH]1)C(=O)N1C[C@]2(C[C@H]1C#N)C(=O)Nc1ccccc21
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM554019(US11325916, Example 46)
Show SMILES CC(C)C[C@H](N(C)C(=O)[C@H](CC(C)(C)C)NC(=O)c1cc2c(F)cc(F)c(F)c2[nH]1)C(=O)N1C[C@]2(C[C@H]1C#N)C(=O)Nc1ccccc21
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM554020(US11325916, Example 47)
Show SMILES CC(C)[C@H](NC(=O)OC(C)(C)C)C(=O)N(C)[C@@H](Cc1ccccc1)C(=O)N1C[C@]2(C[C@H]1C#N)C(=O)Nc1ccccc21
Show InChI InChI=1S/C32H39N5O5/c1-20(2)26(35-30(41)42-31(3,4)5)28(39)36(6)25(16-21-12-8-7-9-13-21)27(38)37-19-32(17-22(37)18-33)23-14-10-11-15-24(23)34-29(32)40/h7-15,20,22,25-26H,16-17,19H2,1-6H3,(H,34,40)(H,35,41)/t22-,25-,26-,32-/m0/s1
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM554021(US11325916, Example 48)
Show SMILES CC(C)[C@@H](NC(=O)OC(C)(C)C)C(=O)N(C)[C@@H](Cc1ccccc1)C(=O)N1C[C@]2(C[C@H]1C#N)C(=O)Nc1ccccc21
Show InChI InChI=1S/C32H39N5O5/c1-20(2)26(35-30(41)42-31(3,4)5)28(39)36(6)25(16-21-12-8-7-9-13-21)27(38)37-19-32(17-22(37)18-33)23-14-10-11-15-24(23)34-29(32)40/h7-15,20,22,25-26H,16-17,19H2,1-6H3,(H,34,40)(H,35,41)/t22-,25-,26+,32-/m0/s1
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM554022(US11325916, Example 49)
Show SMILES CC(C)C[C@H](N(C)C(=O)[C@@H](NC(=O)OCc1ccccc1)C(C)C)C(=O)N1C[C@]2(C[C@H]1C#N)C(=O)Nc1ccccc21
Show InChI InChI=1S/C32H39N5O5/c1-20(2)15-26(36(5)29(39)27(21(3)4)35-31(41)42-18-22-11-7-6-8-12-22)28(38)37-19-32(16-23(37)17-33)24-13-9-10-14-25(24)34-30(32)40/h6-14,20-21,23,26-27H,15-16,18-19H2,1-5H3,(H,34,40)(H,35,41)/t23-,26-,27-,32-/m0/s1
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM554024(US11325916, Example 51)
Show SMILES CC(C)[C@@H](NC(F)=O)C(=O)N(C)[C@@H](Cc1ccccc1)C(=O)N1C[C@]2(C[C@H]1C#N)C(=O)Nc1ccccc21
Show InChI InChI=1S/C28H30FN5O4/c1-17(2)23(32-27(29)38)25(36)33(3)22(13-18-9-5-4-6-10-18)24(35)34-16-28(14-19(34)15-30)20-11-7-8-12-21(20)31-26(28)37/h4-12,17,19,22-23H,13-14,16H2,1-3H3,(H,31,37)(H,32,38)/t19-,22-,23+,28-/m0/s1
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals, Inc.

US Patent
LigandPNGBDBM554025(US11325916, Example 52)
Show SMILES CN([C@@H](CC(C)(C)C)C(=O)N1C[C@]2(C[C@H]1C#N)C(=O)Nc1ccccc21)C(=O)[C@H](Cc1ccc(F)cc1)N1CCOC1=O
Show InChI InChI=1S/C32H36FN5O5/c1-31(2,3)17-26(28(40)38-19-32(16-22(38)18-34)23-7-5-6-8-24(23)35-29(32)41)36(4)27(39)25(37-13-14-43-30(37)42)15-20-9-11-21(33)12-10-20/h5-12,22,25-26H,13-17,19H2,1-4H3,(H,35,41)/t22-,25-,26-,32-/m0/s1
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
Displayed 1 to 50 (of 135 total ) | Next | Last >>
Jump to: